Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia

详细信息    查看全文

• 作者：Séverine Loisel (1)
  Pierre-Alain André (2)
  Josee Golay (3)
  Franz Buchegger (2) (4)
  Jean Kadouche (5)
  Martine Cérutti (6)
  Luca Bologna (3)
  Marek Kosinski (2) (7)
  David Viertl (2)
  Angelika Bischof Delaloye (2)
  Christian Berthou (1)
  Jean-Pierre Mach (8)
  Laurence Boumsell (9)
  
• 刊名：Molecular Cancer
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：10
• 期：1
• 全文大小：426KB
• 参考文献：1. Boumsell L, Bernard A, Lepage V, Degos L, Lemerle J, Dausset J: Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T cells. / Eur J Immunol 1978, 8:900-04. CrossRef
  2. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ, Sison CP, Allen SL, Kolitz J, Schulman P, / et al.: B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. / Blood 2002, 99:4087-093. CrossRef
  3. Friedlein G, El Hage F, Vergnon I, Richon C, Saulnier P, Lecluse Y, Caignard A, Boumsell L, Bismuth G, Chouaib S, Mami-Chouaib F: Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. / J Immunol 2007, 178:6821-827.
  4. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH: Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. / Blood 2002, 100:4537-543. CrossRef
  5. Dillman RO, Shawler DL, Dillman JB, Royston I: Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. / J Clin Oncol 1984, 2:881-91.
  6. Miller RA, Oseroff AR, Stratte PT, Levy R: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. / Blood 1983, 62:988-95.
  7. Hertler AA, Schlossman DM, Borowitz MJ, Laurent G, Jansen FK, Schmidt C, Frankel AE: A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. / J Biol Response Mod 1988, 7:97-13.
  8. Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, Neumann RD, Boland C, Perentesis P, Brown MR, / et al.: Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. / Clin Cancer Res 1998, 4:2691-700.
  9. Cioca DP, Kitano K: Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia. / Leukemia 2002, 16:335-43. CrossRef
  10. Pers JO, Berthou C, Porakishvili N, Burdjanadze M, Le Calvez G, Abgrall JF, Lydyard PM, Youinou P, Jamin C: CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia. / Leukemia 2002, 16:44-2. CrossRef
  11. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML: The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. / Clin Immunol 2006, 121:144-58. CrossRef
  12. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY: Transferrin receptors in human tissues: their distribution and possible clinical relevance. / J Clin Pathol 1983, 36:539-45. CrossRef
  13. Das Gupta A, Shah VI: Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. / Hematol Pathol 1990, 4:37-1.
  14. Taetle R, Honeysett JM, Trowbridge I: Effects of anti-transferrin receptor antibodies on growth of normal and malignant myeloid cells. / Int J Cancer 1983, 32:343-49. CrossRef
  15. Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht TT, Kornfeld S, Taetle R: Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. / Clin Cancer Res 1995, 1:1259-265.
  16. Qing Y, Shuo W, Zhihua W, Huifen Z, Ping L, Lijiang L, Xiaorong Z, Liming C, Daiwen X, Yu H, / et al.: The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor. / Cancer Immunol Immunother 2006, 55:1111-121. CrossRef
  17. Kaufman JF, Auffray C, Korman AJ, Shackelford DA, Strominger J: The class II molecules of the human and murine major histocompatibility complex. / Cell 1984, 36:1-3. CrossRef
  18. Newell MK, VanderWall J, Beard KS, Freed JH: Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. / Proc Natl Acad Sci USA 1993, 90:10459-0463. CrossRef
  19. Yoshino T, Cao L, Nishiuchi R, Matsuo Y, Yamadori I, Kondo E, Teramoto N, Hayashi K, Takahashi K, Kamikawaji N, / et al.: Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO-1)-mediated apoptosis. / Eur J Immunol 1995, 25:2190-194. CrossRef
  20. Golay J, Bologna L, André PA, Buchegger F, Mach JP, Boumsell L, Introna M: Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. / Blood 2010, 116:3372-. CrossRef
  21. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. / Cancer 1997, 80:2706-711. CrossRef
  22. Brown KS, Levitt DJ, Shannon M, Link BK: Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma. / Clin Lymphoma 2001, 2:188-90. CrossRef
  23. Dunleavy K, White T, Grant N, Shovlin M, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Marti G, Janik J, Wilson WH: Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia. / J Clin Oncol (Meeting Abstracts) 2005, 23:6607.
  24. Kansas GS, Tedder TF: Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. / J Immunol 1991, 147:4094-102.
  25. Mourad W, Geha RS, Chatila T: Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule 1-dependent cell adhesion. / J Exp Med 1990, 172:1513-516. CrossRef
  26. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. / J Exp Med 2004, 199:1659-669. CrossRef
  27. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J: M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. / J Immunol 2009, 182:4415-422. CrossRef
  28. Introna M, Golay J: Complement in antibody therapy: friend or foe? / Blood 2009, 114:5247-248. CrossRef
  29. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. / Nat Med 2000, 6:443-46. CrossRef
  30. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. / Blood 2002, 99:754-58. CrossRef
  31. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, / et al.: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. / J Clin Oncol 2008, 26:1789-796. CrossRef
  32. Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pelegrin A, Azria D: Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. / Ann Oncol 21:98-03.
  33. Bondada S, Bikah G, Robertson DA, Sen G: Role of CD5 in growth regulation of B-1 cells. / Curr Top Microbiol Immunol 2000, 252:141-49.
  34. Folkman J: Angiogenesis. / Annu Rev Med 2006, 57:1-8. CrossRef
  35. Dechant M, Bruenke J, Valerius T: HLA class II antibodies in the treatment of hematologic malignancies. / Semin Oncol 2003, 30:465-75. CrossRef
  36. Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, Coleman M, Goldenberg DM: Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. / Cancer 2008, 113:2714-723. CrossRef
  37. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, / et al.: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. / Blood 2003, 101:3413-415. CrossRef
  38. Nabhan C, Patton D, Gordon LI, Riley MB, Kuzel T, Tallman MS, Rosen ST: A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). / Leuk Lymphoma 2004, 45:2269-273. CrossRef
  39. Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE, Hicklin DJ: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. / Clin Cancer Res 2006, 12:2197-207. CrossRef
  40. Larbouret C, Robert B, Navarro-Teulon I, Thezenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pelegrin A, Azria D: In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. / Clin Cancer Res 2007, 13:3356-362. CrossRef
  41. Loisel S, Ster KL, Quintin-Roue I, Pers JO, Bordron A, Youinou P, Berthou C: Establishment of a novel human B-CLL-like xenograft model in nude mouse. / Leuk Res 2005, 29:1347-352. CrossRef
  42. Rickers A, Peters N, Badock V, Beyaert R, Vandenabeele P, Dorken B, Bommert K: Cleavage of transcription factor SP1 by caspases during anti-IgM-induced B-cell apoptosis. / Eur J Biochem 1999, 261:269-74. CrossRef
  43. Schaffland AO, Buchegger F, Kosinski M, Antonescu C, Paschoud C, Grannavel C, Pellikka R, Delaloye AB: 131I-rituximab: relationship between immunoreactivity and specific activity. / J Nucl Med 2004, 45:1784-790.
  44. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr: Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. / J Immunol Methods 1984, 72:77-9. CrossRef
  45. Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, van Rooijen N, Vago L, Introna M: The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. / Haematologica 2006, 91:176-83.
  
• 作者单位：Séverine Loisel (1)
  Pierre-Alain André (2)
  Josee Golay (3)
  Franz Buchegger (2) (4)
  Jean Kadouche (5)
  Martine Cérutti (6)
  Luca Bologna (3)
  Marek Kosinski (2) (7)
  David Viertl (2)
  Angelika Bischof Delaloye (2)
  Christian Berthou (1)
  Jean-Pierre Mach (8)
  Laurence Boumsell (9)
  
  1. EA2216 and IFR148, University Medical School, Université Européenne de Bretagne, F-9238, Brest, France
  2. Service of Nuclear Medicine, University Hospital of Lausanne, CH-1011, Lausanne, Switzerland
  3. Laboratory of Cellular Therapy, USC Ematologia, c/o Presidio Matteo Rota, Ospedali Riuniti, I-24128, Bergamo, Italy
  4. Service of Nuclear Medicine, University Hospital of Geneva, CH-1211, Geneva 14, Switzerland
  5. MAT Biopharma, MAT Ltd., F-91030, Evry Cedex, France
  6. Centre National de La Recherche Scientifique (CNRS) UPS 3044, Unité Baculovirus et Thérapie, F-30380, Saint-Christol-lès-Alès, France
  7. Institute of Applied Radiophysics, University of Lausanne, CH-1007, Lausanne, Switzerland
  8. Department of Biochemistry, University of Lausanne, CH1066, Epalinges, Switzerland
  9. Institut National de la Santé et de la Recherche Médicale, U1016, Université de Paris V, Paris, France
  
• ISSN：1476-4598

文摘

Background The increasing availability of different monoclonal antibodies (mAbs) opens the way to more specific biologic therapy of cancer patients. However, despite the significant success of therapy in breast and ovarian carcinomas with anti-HER2 mAbs as well as in non-Hodkin B cell lymphomas with anti-CD20 mAbs, certain B cell malignancies such as B chronic lymphocytic leukaemia (B-CLL) respond poorly to anti-CD20 mAb, due to the low surface expression of this molecule. Thus, new mAbs adapted to each types of tumour will help to develop personalised mAb treatment. To this aim, we analyse the biological and therapeutic properties of three mAbs directed against the CD5, CD71 or HLA-DR molecules highly expressed on B-CLL cells. Results The three mAbs, after purification and radiolabelling demonstrated high and specific binding capacity to various human leukaemia target cells. Further in vitro analysis showed that mAb anti-CD5 induced neither growth inhibition nor apoptosis, mAb anti-CD71 induced proliferation inhibition with no early sign of cell death and mAb anti-HLA-DR induced specific cell aggregation, but without evidence of apoptosis. All three mAbs induced various degrees of ADCC by NK cells, as well as phagocytosis by macrophages. Only the anti-HLA-DR mAb induced complement mediated lysis. Coincubation of different pairs of mAbs did not significantly modify the in vitro results. In contrast with these discrete and heterogeneous in vitro effects, in vivo the three mAbs demonstrated marked anti-tumour efficacy and prolongation of mice survival in two models of SCID mice, grafted either intraperitoneally or intravenously with the CD5 transfected JOK1-5.3 cells. This cell line was derived from a human hairy cell leukaemia, a type of malignancy known to have very similar biological properties as the B-CLL, whose cells constitutively express CD5. Interestingly, the combined injection of anti-CD5 with anti-HLA-DR or with anti-CD71 led to longer mouse survival, as compared to single mAb injection, up to complete inhibition of tumour growth in 100% mice treated with both anti-HLA-DR and anti-CD5. Conclusions Altogether these data suggest that the combined use of two mAbs, such as anti-HLA-DR and anti-CD5, may significantly enhance their therapeutic potential.